The iMacs become established in the liver, reshaping the inflammatory potential in the liver that may drive progression to cirrhosis or affect the outcome of immunotherapy by providing a liver-restricted niche for CD8+ T cell activity. The gene discussed is CD8A; the disease is Cirrhosis.